PHARMACEUTICAL 2024

Abbott Laboratories
Rank 22 of 309

Abbott



Abbott Laboratories
Rank 22 of 309

The relative strengths and weaknesses of Abbott Laboratories are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Abbott Laboratories compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 94% points.The greatest weakness of Abbott Laboratories is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 24% points.

The company's Economic Capital Ratio, given in the ranking table, is 376%, being 163% points above the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	22,670,000
Cost of Goods Sold	17,975,000
Intangible Assets	32,494,000
Liabilities, Current	13,841,000
Liabilities, Non-Current	0
Other Assets	7,896,000
Other Compr. Net Income	212,000
Other Expenses	3,544,000
Other Liabilities	0
Other Net Income	823,000
Other Revenues	40,109,000
Property and Equipment	10,154,000
Research and Development	2,741,000
Selling, General and Administrative Expense	10,949,000

Output Variable	Value in 1000 USD
Assets	73,214,000
Liabilities	13,841,000
Expenses	35,209,000
Revenues	40,109,000
Stockholders Equity	59,373,000
Net Income	5,723,000
Comprehensive Net Income	5,829,000
BaseVar	81,704,000
ECR before LimitedLiability	311%
Economic Capital Ratio	376%